Clinical Trial Search

Primary: Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core) — 90; 109; 25; 59 Participants

Primary: Weight Change — 6.5; 6.3 kg

Primary: Peak Plasma Concentration (Cmax) — 85.87 mg/L

Primary: Number of Oocytes Retrieved Per Patient — 11.3; 12.4 Oocytes — p=0.9

Primary: Success Rate of Placement of a Thoracic Epidural — 41; 45 Participants

Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001

Primary: Change in Urine Uric Acid Concentration (Increased Solubility) by Assay — 23.81; 22.30 mg/dl

Primary: Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment — 15.03; 14.93 events per…

Primary: Mean Number of Adherent Sets of Symbicort Puffs Per Day Over the 26-Week Study Period — 1.3; 1.6 Adherent sets of puffs / day — p=<0.001

Primary: Percentage of Patients With iPTH Serum Concentration >110 pg/mL. — 9; 16; 32; 27 Participants — p=0.0083

Primary: Change From Baseline in Postoperative Pain — 20.5; 29.2; 20.7; 20.1 units on a scale — p=<0.05

Primary: Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5. — -3.52; -3.13 units on a scale

Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 1.93; 2.26; 1.83; 2.58 units on a scale

Primary: Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine — 37; 40.5 pounds

Primary: Mean Change From Baseline (on PGA) in Diurnal IOP (Mean of 09:00 and 11:00 Time Points) at Week 6 — -5.6; -2.1 mmHg — p=< 0.001